Find out more about the latest RNA drug development

Find out more about the latest RNA drug development

22.08.2023 Munich’s leading researchers have preclinically evaluated an active RNA Drug called RCS-21 to prevent severe pneumonia and fibrosis, caused by infections such as SARS-CoV2 (Beck et al. 2023). Macrophage-targeted carbohydrate-coupled antimiR-21 (RCS-21) enables an efficient transport mechanism to pathological tissues and inhibits the activity of the microRNA 21 molecule. AntimiR-21 oligos were synthesized and modified with Trimannose and GalNac depending on baseclick patented technology. Modified antimir-21 exhibited a distinct cellular targeting in tissue. We are proud to support the idea development of our partners based on our expertise.